Q-omics provides the consensus-scored ZNF831 profile across patient tissues and cancer cell-line models. ZNF831 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF831 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, ZNF831 RNA expression shows 20,554 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where ZNF831 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF831 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF831 survival associations across molecular data types. ZNF831 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF831 RNA expression–survival associations across cancer types. High ZNF831 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, CESC, LUAD and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF831 RNA expression.
This table summarizes ZNF831 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF831. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF831 shows lower tumor expression in COAD, LUSC, THCA and UCEC and higher tumor expression in KIRC and STAD. The KIRC box plot shows higher ZNF831 RNA expression in tumor versus normal tissue (log2 FC = +0.754, t-test p < 0.001).
This table shows molecular features associated with ZNF831 in patient tissues and cancer cell lines. In patient samples, ZNF831 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF831 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
